SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
Jurgis Bekepuris
To: MNTNH who wrote (57235)5/3/2016 6:32:26 AM
From: Ditchdigger1 Recommendation  Read Replies (1) of 78750
 
Is that $80k the list price or negotiated price for GILD's drug. I haven't followed this sector in 4 or 5 years(was following VRTX), what's the cure rate of these drugs now, 90% +.
Quick back of the hand calc.
10 years ago, the cure rate(sustained virologic response) was about 50/50, after having completed a 48 week course of treatment. Drugs used were peginterferon and ribavirin. $1000/wk for the drugs ($48,000).
During the course of treatment dozens of CBC blood tests, as well as dozens of viral load pcr tests were done ($15,000+) in order to monitor treatment progression. Many couldn't complete the full treatment.
Chances are during treatment blood booster drugs would be needed (whites/hgb) in order for the patient to even complete the full 48 week course of treatment ($20,000+)
The treatment was only administered by a specialist (hepatologist/gastro) and closely monitored over the 48 weeks at a much higher cost than a GP.
Chances of successful treatment (svr), 60% at best. Many relapsed after completing the treatment and would have to be retreated again. (start doubling costs)

As I said, Hep C treatment costs have not increased much in a decade.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext